| 产品标题 |
产品货号 |
产品规格 |
厂家 |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 1 from ORIGENE TECHNOLOGIES | LY424181 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 2 (ANAPC2) from ORIGENE TECHNOLOGIES | LY402247 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 3 from ORIGENE TECHNOLOGIES | LY424182 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 3 from ORIGENE TECHNOLOGIES | LY425074 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 4 from ORIGENE TECHNOLOGIES | LY424183 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 5 from ORIGENE TECHNOLOGIES | LY424184 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 2 from ORIGENE TECHNOLOGIES | LY413973 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 6 from ORIGENE TECHNOLOGIES | LY424185 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 7 from ORIGENE TECHNOLOGIES | LY424186 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 4 from ORIGENE TECHNOLOGIES | LY425075 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 7 from ORIGENE TECHNOLOGIES | LY425077 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 11 (ANAPC11), transcript variant 6 from ORIGENE TECHNOLOGIES | LY425076 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 13 (ANAPC13), transcript variant 1 from ORIGENE TECHNOLOGIES | LY414554 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 7 (ANAPC7), transcript variant 1 from ORIGENE TECHNOLOGIES | LY414102 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaphase promoting complex subunit 5 (ANAPC5), transcript variant 1 from ORIGENE TECHNOLOGIES | LY402524 | 100 ug | ORIGENE TECHNOLOGIES |
| Anaplastic lymphoma receptor tyrosine kinase (ALK) from ORIGENE TECHNOLOGIES | LY418072 | 100 ug | ORIGENE TECHNOLOGIES |
| Androgen-induced 1 (AIG1) from ORIGENE TECHNOLOGIES | LY414183 | 100 ug | ORIGENE TECHNOLOGIES |
| Androstenedione ELISA Kit from ORIGENE TECHNOLOGIES | EA101045 | 96-well strip plate | ORIGENE TECHNOLOGIES |
| Androgen receptor (AR), transcript variant 2 from ORIGENE TECHNOLOGIES | LY423281 | 100 ug | ORIGENE TECHNOLOGIES |
| Androgen receptor (AR), transcript variant 1 from ORIGENE TECHNOLOGIES | LY400012 | 100 ug | ORIGENE TECHNOLOGIES |
| Angel homolog 1 (Drosophila) (ANGEL1) from ORIGENE TECHNOLOGIES | LY414639 | 100 ug | ORIGENE TECHNOLOGIES |
| Angel homolog 2 (Drosophila) (ANGEL2) from ORIGENE TECHNOLOGIES | LY408277 | 100 ug | ORIGENE TECHNOLOGIES |
| Angel1 - KN2.0, Mouse gene knockout kit via CRISPR from ORIGENE TECHNOLOGIES | KN501234 | 1 kit | ORIGENE TECHNOLOGIES |
| ANGEL2 - KN2.0, Human gene knockout kit via CRISPR from ORIGENE TECHNOLOGIES | KN416492 | 1 kit | ORIGENE TECHNOLOGIES |
| ANGEL1 - KN2.0, Human gene knockout kit via CRISPR from ORIGENE TECHNOLOGIES | KN405599 | 1 kit | ORIGENE TECHNOLOGIES |
| Angel2 - KN2.0, Mouse gene knockout kit via CRISPR from ORIGENE TECHNOLOGIES | KN501235 | 1 kit | ORIGENE TECHNOLOGIES |
| ANGEL2 Mass Spectrometry Standard from ORIGENE TECHNOLOGIES | PH316492 | 10 ug | ORIGENE TECHNOLOGIES |
| ANGEL1 Mass Spectrometry Standard from ORIGENE TECHNOLOGIES | PH305599 | 10 ug | ORIGENE TECHNOLOGIES |
| Angiogenin, ribonuclease, RNase A family, 5 (ANG), transcript variant 1 from ORIGENE TECHNOLOGIES | LY420108 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiogenin, ribonuclease, RNase A family, 5 (ANG), transcript variant 2 from ORIGENE TECHNOLOGIES | LY420124 | 100 ug | ORIGENE TECHNOLOGIES |
| Angio-associated, migratory cell protein (AAMP) from ORIGENE TECHNOLOGIES | LY421332 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiogenin, ribonuclease, RNase A family, 5 (ANG), transcript variant 2 from ORIGENE TECHNOLOGIES | LY425988 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiomotin (AMOT), transcript variant 2 from ORIGENE TECHNOLOGIES | LY408854 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiomotin like 2 (AMOTL2) from ORIGENE TECHNOLOGIES | LY414133 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin 1 (ANGPT1) from ORIGENE TECHNOLOGIES | LY400458 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin 4 (ANGPT4) from ORIGENE TECHNOLOGIES | LY414259 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiomotin like 1 (AMOTL1) from ORIGENE TECHNOLOGIES | LY408899 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin 2 (ANGPT2), transcript variant 1 from ORIGENE TECHNOLOGIES | LY400459 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin 2 (ANGPT2), transcript variant 3 from ORIGENE TECHNOLOGIES | LY426530 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin-like 3 (ANGPTL3) from ORIGENE TECHNOLOGIES | LY402339 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin-like 1 (ANGPTL1) from ORIGENE TECHNOLOGIES | LY401482 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin-like 2 (ANGPTL2) from ORIGENE TECHNOLOGIES | LY402146 | 100 ug | ORIGENE TECHNOLOGIES |
| Angiopoietin-like 5 (ANGPTL5) from ORIGENE TECHNOLOGIES | LY403602 | 100 ug | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, acute from ORIGENE TECHNOLOGIES | CS544910 | 5x5um | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, acute from ORIGENE TECHNOLOGIES | CS550636 | 5x5um | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, acute from ORIGENE TECHNOLOGIES | CS600589 | 5x5um | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, acute from ORIGENE TECHNOLOGIES | CS600425 | 5x5um | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, acute from ORIGENE TECHNOLOGIES | CS600590 | 5x5um | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, chronic from ORIGENE TECHNOLOGIES | CS701081 | 5x5um | ORIGENE TECHNOLOGIES |
| Human Prostate; Prostatitis, chronic from ORIGENE TECHNOLOGIES | CS701084 | 5x5um | ORIGENE TECHNOLOGIES |